Luethi, D; Kaeser, PJ; Brandt, SD; Krähenbühl, S; Hoener, MC; Liechti, ME. Pharmacological profile of methylphenidate-based designer drugs. Neuropharmacology, 18 Aug 2017, n/a. 987 kB. https://doi.org/10.1016/j.neuropharm.2017.08.020
Roman, DL; Saldaña, SN; Nichols, DE; Carroll, FI; Barker, EL. Distinct molecular recognition of psychostimulants by human and Drosophila serotonin transporters. J. Pharmacol. Exp. Ther., 1 Jan 2004, 308 (2), 679–687. 519 kB. https://doi.org/10.1124/jpet.103.057836
Brandt, SD; Kavanagh, PV. Addressing the challenges in forensic drug chemistry. Drug Test. Analysis, 1 Mar 2017, 9 (3), 342-346. 120 kB. https://doi.org/10.1002/dta.2169
Burns, L; Roxburgh, A; Bruno, R; Van Buskirk, J. Monitoring drug markets in the Internet age and the evolution of drug monitoring systems in Australia. Drug Test. Analysis, 1 Jul 2014, 6 (7-8), 840-845. 113 kB. https://doi.org/10.1002/dta.1613
Vidal Giné, C; Espinosa, IF; Vilamala, MV. New psychoactive substances as adulterants of controlled drugs. A worrying phenomenon? Drug Test. Analysis, 1 Jul 2014, 6 (7-8), 819-824. 113 kB. https://doi.org/10.1002/dta.1610
Wilkins, C; Sweetsur, P. The impact of the prohibition of benzylpiperazine (BZP) ‘legal highs’ on the prevalence of BZP, new legal highs and other drug use in New Zealand. Drug Alcohol Depend., 1 Jan 2013, 127 (1-3), 72-80. 521 kB. https://doi.org/10.1016/j.drugalcdep.2012.06.014
Nichols, DE; Oberlender, R. Structure-activity relationships of MDMA-like substances. In Pharmacology and Toxicology of Amphetamine and Related Designer Drugs. NIDA Research Monograph 94; Asghar, K; De Souza, E, Eds., U.S. Department of Health and Human Services, National Institute of Health, U.S. Government Printing Office, Washington, DC, 1 Jan 1989; pp 1-29. 282 kB.
Plowman, T; Rivier, L. Cocaine and cinnamoylcocaine content of Erythroxylum species. Ann. Bot., 1 May 1983, 51 (5), 641–659. 1.0 MB. https://doi.org/10.1093/oxfordjournals.aob.a086511 #Cocaine
Lurie, IS; Bethea, MJ; McKibben, TD; Hays, PA; Pellegrini, P; Sahai, R; Garcia, AD; Weinberger, R. Use of dynamically coated capillaries for the routine analysis of methamphetamine, amphetamine, MDA, MDMA, MDEA, and cocaine using capillary electrophoresis. J. Forensic Sci., 1 Sep 2001, 46 (5), 1025–1032. 346 kB. https://doi.org/10.1520/JFS15096J #Cocaine other
Young, R; Glennon, RA. Cocaine-stimulus generalization to two new designer drugs: Methcathinone and 4-methylaminorex. Pharmacol. Biochem. Behav., 1 May 1993, 45 (1), 209–214. 224 kB. https://doi.org/10.1016/0091-3057(93)90110-F #Cocaine
Walline, CC; Nichols, DE; Carroll, FI; Barker, EL. Comparative molecular field analysis using selectivity fields reveals residues in the third transmembrane helix of the serotonin transporter associated with substrate and antagonist recognition. J. Pharmacol. Exp. Ther., 1 Jun 2008, 325 (3), 791–800. 269 kB. https://doi.org/10.1124/jpet.108.136200 #Cocaine
Johnson, MW; Griffiths, RR; Hendricks, PS; Henningfield, JE. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology, 1 Jun 2018, n/a. 2.5 MB. https://doi.org/10.1016/j.neuropharm.2018.05.012 #Cocaine
Nichols, DE. CNS Stimulants. In Burger's Medicinal Chemistry and Drug Discovery; Abraham, DJ, Ed., John Wiley & Sons, Inc., 29 Jan 2010; pp 89–120. 1.8 MB. https://doi.org/10.1002/0471266949.bmc243 #3
Drake, LR; Scott, PJH. DARK classics in chemical neuroscience: Cocaine. ACS Chem. Neurosci., 17 Oct 2018, 9 (10), 2358–2372. 30.3 MB. https://doi.org/10.1021/acschemneuro.8b00117 #1
Chambers, SA; DeSousa, JM; Huseman, ED; Townsend, SD. The DARK side of total synthesis: Strategies and tactics in psychoactive drug production. ACS Chem. Neurosci., 17 Oct 2018, 9 (10), 2307–2330. 8.1 MB. https://doi.org/10.1021/acschemneuro.7b00528 #122
Passie, T; Brandt, SD. Self-experiments with psychoactive substances: A historical perspective. In New Psychoactive Substances : Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 69-110. 563 kB. https://doi.org/10.1007/164_2018_177 #Cocaine
Casale, JF; Hays, PA. Characterization of 2β-(1,2,4-oxadiazol-5-methyl)-3β-phenyltropane (“RTI-126”). Microgram J., 1 Jan 2011, 8 (1), 3–11. 682 kB. #1 GC,MS,NMR,IR
Baumann, MH; Walters, HM; Niello, M; Sitte, HH. Neuropharmacology of synthetic cathinones. In New Psychoactive Substances : Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 113–142. 409 kB. https://doi.org/10.1007/164_2018_178 #Cocaine
Luethi, D; Liechti, ME. Monoamine transporter and receptor interaction profiles in vitro predict reported human doses of novel psychoactive stimulants and psychedelics. Int. J. Neuropsychoph., 1 Oct 2018, 21 (10), 926–931. 254 kB. https://doi.org/10.1093/ijnp/pyy047 #S1 Other Cocaine